Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time

Journal of Visualized Experiments

Volumn , Issue 87, 2014, Pages

  Bilandzic, Maree ^a   Stenvers, Kaye L ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Invasion; Issue 87; Medicine; Mesothelial cells; Metastasis; Ovarian cancer; Real time analysis; Spheroids

Indexed keywords

EID: 84921891800     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51655     Document Type: Article

References (18)

1. Ferlay, J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127, 2893-2917, doi:10.1002/ijc.25516 (2010).
2. Ahmed, N., & Stenvers, K. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Frontiers in Oncology. 3, doi:10.3389/fonc.2013.00256 (2013).
3. Karst, A. M., & Drapkin, R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010, 932371, doi:10.1155/2010/932371 (2010).
4. Lengyel, E. Ovarian cancer development and metastasis. Am J Pathol. 177, 1053-1064, doi:S0002-9440(10)60160-5 [pii]10.2353/ajpath.2010.100105 (2010).
5. Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol. 113, 143-148, doi:S0090-8258(08)00974-8 [pii]10.1016/j.ygyno.2008.11.032 (2009).
6. Hudson, L. G., Zeineldin, R., & Stack, M. S. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis. 25, 643-655, doi:10.1007/s10585-008-9171-5 (2008).
7. Burleson, K. M., Boente, M. P., Pambuccian, S. E., & Skubitz, A. P. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 4, 6, doi:1479-5876-4-6 [pii]10.1186/1479-5876-4-6 (2006).
8. Burleson, K. M., et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 93, 170-181, doi:10.1016/j.ygyno.2003.12.034 S0090825803009508 [pii] (2004).
9. Burleson, K. M., Hansen, L. K., & Skubitz, A. P. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 21, 685-697 (2004).
10. Kenny, H. A., Kaur, S., Coussens, L. M., & Lengyel, E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 118, 1367-1379, doi:10.1172/JCI33775 (2008).
11. Kenny, H. A., Nieman, K. M., Mitra, A. K., & Lengyel, E. The First Line of Abdominal Metastatic Attack: Breaching the Mesothelial Cell Layer. Cancer Discov. 1, 100-102, doi:10.1158/2159-8290.CD-11-0117 (2011).
12. Hattermann, K., Held-Feindt, J., & Mentlein, R. Spheroid confrontation assay: a simple method to monitor the three-dimensional migration of different cell types in vitro. Ann Anat. 193, 181-184, doi:S0940-9602(11)00035-5 [pii] 10.1016/j.aanat.2010.12.005 (2011).
13. Laib, A. M., et al. Spheroid-based human endothelial cell microvessel formation in vivo. Nat Protoc. 4, 1202-1215, doi:nprot.2009.96 [pii] 10.1038/nprot.2009.96 (2009).
14. Latifi, A., et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 7, e46858, doi:10.1371/journal.pone.0046858 PONE-D-12-20118 [pii] (2012).
15. Davidowitz, R. A., Iwanicki, M. P., & Brugge, J. S. In vitro mesothelial clearance assay that models the early steps of ovarian cancer metastasis. J Vis Exp. (60), doi:10.3791/3888 (2012).
16. Iwanicki, M. P., et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 1, 144-157, doi:10.1158/2159-8274.CD-11-0010 (2011).
17. Nishi, Y., et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology. 142, 437-445 (2001).
18. Xu, F., et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res. 5, 3653-3660 (1999).